Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

681
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
681
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

2.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.7K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

6.1K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanosensing by T cells promotes a tissue-resident memory transcriptional program.

Nature immunology·2026
Same author

PD-1 regulates latent effector differentiation of thymic cytotoxic CD8<sup>+</sup> T cells.

Nature communications·2026
Same author

TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris.

medRxiv : the preprint server for health sciences·2026
Same author

KLF2 overrides the resident memory CD8 T cell differentiation program, in opposition to KLF3.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

IL-4-STAT6 signaling delays protective CD8<sup>+</sup> T cell bystander activation by antagonizing IL-18 sensing.

Nature immunology·2026
Same author

Regulatory T-cell Sensing of Extracellular ATP via P2RX7 Promotes Their Accumulation and Suppression and Drives Lung Tumor Growth.

Cancer immunology research·2026

Related Experiment Video

Updated: Sep 22, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.6K

P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy.

Kelsey M Wanhainen1, Changwei Peng1, Maggie H Zhou2

  • 1University of Minnesota Center for Immunology, Masonic Cancer Center, Department of Laboratory Medicine and Pathology, Minneapolis, Minnesota.

Cancer Immunology Research
|May 19, 2022
PubMed
Summary

The purinergic receptor P2RX7 on CD8+ T cells is crucial for controlling melanoma. Stimulating P2RX7 enhances T-cell function and improves tumor elimination, offering a potential immunotherapy strategy.

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.9K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.8K

Related Experiment Videos

Last Updated: Sep 22, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.6K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.9K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.8K

Area of Science:

  • Immunology
  • Cancer Biology
  • Cellular Biology

Background:

  • The purinergic receptor P2RX7 expressed by CD8+ T cells aids memory formation after infections.
  • However, P2RX7's role in antitumor immunity is debated, with some evidence suggesting it may hinder responses.

Purpose of the Study:

  • To investigate the role of P2RX7 in CD8+ T-cell-mediated melanoma control.
  • To determine if P2RX7 stimulation can enhance antitumor immunotherapy.

Main Methods:

  • Utilized a mouse CD8+ T-cell adoptive transfer model for melanoma.
  • Assessed P2RX7 function in P2rx7-/- CD8+ T cells regarding mitochondrial health, proliferation, and apoptosis.
  • Investigated the effect of P2RX7 stimulation with BzATP on melanoma control.

Main Results:

  • P2RX7-deficient CD8+ T cells showed impaired mitochondrial function and maintenance.
  • Loss of P2RX7 led to reduced CD8+ T-cell frequency, proliferation, and increased apoptosis in tumors as burden increased.
  • In vitro stimulation of P2RX7 enhanced melanoma control by CD8+ T cells.

Conclusions:

  • P2RX7 expression on CD8+ T cells is essential for effective melanoma control by promoting mitochondrial fitness.
  • Extracellular ATP (eATP) sensing via P2RX7 is critical for CD8+ T-cell antitumor efficacy.
  • P2RX7 stimulation represents a promising therapeutic target for enhancing cancer immunotherapy.